Company Focus
Merck KGaA
Latest Merck KGaA News
Pharmaceutical
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
Related News
Insights
Company Spotlight
Dewpoint is a biotech company pioneering the application of biomolecular condensate biology – the science studying the organization of biomolecules within membrane-less compartments – towards the development of a new generation of therapeutics to address diseases of high unmet need.
Latest News & Features of interest to Merck KGaA
Pharmaceutical
Indian drugmakers plan to accelerate their expansion in the Russian pharmaceutical market this year, which will be achieved by the building of several large-scale manufacturing facilities within the territory of the country, reports The Pharma Letter’s local correspondent. 29 February 2024
Pharmaceutical
Cannabinoid and psychedelic medicine company Incannex Healthcare closed 49% higher after Wednesday’s trading. 29 February 2024
Biotechnology
Swiss biotech Idorsia closed down more than 9% at 2.59 francs today, on news of a deal for two of its assets. 28 February 2024
Pharmaceutical
USA-based rare disease Applied Therapeutics today announced that the US Food and Drug Administration (FDA) has accepted the filing of the New Drug Application (NDA) for govorestat (AT-007) for the treatment of classic galactosemia 28 February 2024
Biotechnology
French immunotherapy company OSE Immunotherapeutics was trading more than 50% higher by late Wednesday. 28 February 2024
Pharmaceutical
CNS specialist Minerva Neurosciences lost 59% of its stock market value on Tuesday. 28 February 2024
Biotechnology
US neurodegenerative diseases focussed biotech Denali Therapeutics saw its shares rocket more than 38% to $23.35, on news of a $500 million private placement. 28 February 2024
Pharmaceutical
Belgium’s largest drugmaker UCB today reported earnings results for the full year ended December 31, 2023 with a downturn on sales and earnings, but demonstrating significant achievements and sending its shares up 3.5% to 100.50 euros. 28 February 2024
Biotechnology
The US Food and Drug Administration (FDA) has granted Priority Review of the supplemental Biologics License Application (sBLA) submitted by Denmark's Genmab and US pharma major AbbVie for Epkinly (epcoritamab-bysp). 27 February 2024
Biotechnology
Chinese oncology specialist BeiGene has ended its collaboration with privately-held Shoreline Biosciences. 27 February 2024
Latest In Brief for Merck KGaA
Pharmaceutical
University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Latest Relevant Ones To Watch News
Taiwan-based REGiMMUNE, a biopharma creating immunotherapies through the power of regulatory T cells (Tregs), and France-based Kiji Therapeutics, a specialist in induced pluripotent stem cells-mesenchymal stem cells (IPSC-MSC) engineered cell therapies for inflammatory diseases, are to merge. 18 October 2024
15 October 2024
8 October 2024
8 October 2024
24 September 2024
Relevant Ones to Watch Companies
Refine Search
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze